On September 11, 2024, Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc (MYGN, Financial), sold 2,100 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 108,013 shares of Myriad Genetics Inc.
Myriad Genetics Inc (MYGN, Financial) is a company that focuses on molecular diagnostic testing. These tests assist in assessing an individual's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence.
Over the past year, the insider transaction history at Myriad Genetics Inc shows a total of 11 insider sells and no insider buys. Dale Muzzey's recent transaction follows this trend of insider selling, with the insider having sold a total of 2,100 shares over the past year and purchased none.
On the day of the sale, shares of Myriad Genetics Inc were trading at $26.17. This pricing gives the company a market cap of approximately $2.40 billion. According to the GF Value, the intrinsic value estimate for Myriad Genetics Inc is $23.47 per share, making the stock modestly overvalued with a price-to-GF-Value ratio of 1.12.
The GF Value is calculated based on historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This insider sale might be of interest to current and potential investors, as it provides insight into the actions of key executives within Myriad Genetics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
